ARTICLE | Clinical News
Tendoncel: Phase II data
July 13, 2015 7:00 AM UTC
A double-blind, placebo-controlled Phase II trial in 34 patients with chronic grade 3 lateral epicondylitis showed that once-daily topical Tendoncel for 21 days significantly improved DASH scores by 7...